Year-end Report 1 October – 31 December 2021
· Despite pandemic related challenges: 30% sales growth and surgeries in 15 countries during 2021 · Episurf Medical’s first 510(k) submission completed in line with timetable. FDA review ongoing · Commercial organisation expanded with Head of Sales OUS, re-start of commercial activities following the end of the pandemic”Approaching the end of the pandemic is a relief on a human level, far beyond business life. However, it is fair to say that wearing the Episurf jersey during the pandemic has been extremely tough. Elective surgery has been severely hit, with experimental elective